At a glance
ClinicalIndex Comparison RecordN/ACompleted· 105 enrolled
Drug / intervention
HepaSphere Microspheresdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Registry of Transarterial Chemoembolization of Metastatic Colorectal Cancer to the Liver With HepaSphere™ Microspheres Loaded With Irinotecan
In Brief
An observational study evaluating HepaSphere Microspheres for Metastatic Colorectal Cancer. Completed, enrolled 105 participants across 2 sites in 2 countries.
Detailed Summary
HepaSphere™ Microspheres loaded with irinotecan received CE mark for the indication of use in embolization of metastatic colorectal cancer (mCRC) to the liver in 2015. The purpose of this registry is to demonstrate the safety and efficacy of HepaSphere Microspheres loaded with irinotecan for the treatment of colorectal liver metastasis and add to the understanding of the use and value of this treatment in 'real life' usage conditions.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesFrance, Greece
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedApr 2021
Primary CompletionJun 2021
TodayJul 2026
First PostedApr 29, 2021
Enrollment StartSep 22, 2016
Primary CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 5.2 years ago
Interventions
HepaSphere Microspheresdevice